Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Other(3)

Detailed Status

unknown3
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

unknown360%
completed120%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

NCT04989985
unknownphase_1

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

NCT02317471
unknownphase_3

Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

NCT02512380
completedphase_2

TOF Versus SOX in Metastatic Gastric Cancer

NCT02442362
unknownphase_3

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer

NCT01583361

Clinical Trials (5)

Showing 5 of 5 trials
NCT04989985Phase 2

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

Recruiting
NCT02317471Phase 1

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Unknown
NCT02512380Phase 3

Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

Unknown
NCT02442362Phase 2

TOF Versus SOX in Metastatic Gastric Cancer

Completed
NCT01583361Phase 3

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5